We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
+8.88%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$4.2B
AUM Growth
+$12M
Cap. Flow
-$165M
Cap. Flow %
-3.93%
Top 10 Hldgs %
34.34%
Holding
127
New
6
Increased
36
Reduced
16
Closed
4

Top Buys

Rank Stock Value
1
HUM icon
Humana
HUM
+$21.9M
2
BSX icon
Boston Scientific
BSX
+$14M
3
MRUS
Merus
MRUS
+$10.5M
4
AGL icon
Agilon Health
AGL
+$8.99M
5
BPMC
Blueprint Medicines
BPMC
+$8.35M

Top Sells

Rank Stock Value
1
RXDX
Prometheus Biosciences, Inc. Common Stock
RXDX
+$111M
2
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$40.3M
3
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$25.9M
4
PEN icon
Penumbra
PEN
+$20.7M
5
UNH icon
UnitedHealth
UNH
+$19.6M

Sector Composition

Rank Sector Weight
1 Healthcare 97.12%
2 Consumer Staples 1.04%
3 Industrials 0.9%
4 Financials 0.08%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HUM icon
1
Humana
HUM
$43.9B
$210M 5%
470,000
+43,500
+10% +$21.9M
IMCR icon
2
Immunocore
IMCR
$1.7B
$182M 4.32%
3,028,410
+26,748
+0.9% +$1.53M
PODD icon
3
Insulet
PODD
$11.8B
$161M 3.83%
559,000
+22,250
+4% +$6.76M
AGL icon
4
Agilon Health
AGL
$1.55B
$144M 3.42%
331,300
+16,000
+5% +$8.99M
BPMC
5
DELISTED
Blueprint Medicines
BPMC
$138M 3.29%
2,186,672
+153,624
+8% +$8.35M
ARGX icon
6
argenx
ARGX
$55.2B
$136M 3.25%
350,000
– –
PEN icon
7
Penumbra
PEN
$12.6B
$126M 3%
366,000
-67,500
-16% -$20.7M
NBIX icon
8
Neurocrine Biosciences
NBIX
$18.2B
$121M 2.87%
1,279,500
+69,400
+6% +$6.78M
EVH icon
9
Evolent Health
EVH
$371M
$115M 2.74%
3,803,500
– –
UNH icon
10
UnitedHealth
UNH
$382B
$111M 2.63%
230,000
-40,000
-15% -$19.6M
KRTX
11
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$107M 2.55%
493,527
– –
ISRG icon
12
Intuitive Surgical
ISRG
$127B
$102M 2.43%
298,500
– –
IDXX icon
13
Idexx Laboratories
IDXX
$44.9B
$97.7M 2.32%
194,500
-13,000
-6% -$6.23M
EXAS
14
DELISTED
Exact Sciences
EXAS
$88.6M 2.11%
943,500
+2,000
+0.2% +$156K
CERE
15
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
$79.9M 1.9%
2,513,916
– –
WST icon
16
West Pharmaceutical
WST
$23.7B
$77.3M 1.84%
202,000
– –
SGEN
17
DELISTED
Seagen Inc. Common Stock
SGEN
$77M 1.83%
400,200
– –
ALGN icon
18
Align Technology
ALGN
$12.9B
$76.7M 1.83%
217,000
-30,350
-12% -$9.66M
AGIO icon
19
Agios Pharmaceuticals
AGIO
$2.08B
$76.1M 1.81%
2,686,167
+24,562
+0.9% +$611K
AKRO
20
DELISTED
Akero Therapeutics
AKRO
$72.4M 1.72%
1,550,754
+96,500
+7% +$4.42M
ACHC icon
21
Acadia Healthcare
ACHC
$2.55B
$72.3M 1.72%
908,000
+47,132
+5% +$3.41M
ALNY icon
22
Alnylam Pharmaceuticals
ALNY
$38.3B
$65.5M 1.56%
345,000
– –
RARE icon
23
Ultragenyx Pharmaceutical
RARE
$2.46B
$63.9M 1.52%
1,384,269
+47,868
+4% +$2.22M
DXCM icon
24
DexCom
DXCM
$29B
$63M 1.5%
490,500
– –
EW icon
25
Edwards Lifesciences
EW
$49.4B
$60.9M 1.45%
645,900
– –
1
2 3 4 5

Similar funds

AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
SGI
Summit Global Investments Bountiful, Utah $1.69B AUM 12.13% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
ISS
Intesa Sanpaolo SpA. Turin, Italy $1.69B AUM
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
FDP
Financiere des Professionnels Montreal, Quebec, Canada $1.71B AUM 21.77% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return

Rock Springs Capital Management's Q2 2023 Portfolio in Review

As of Q2 2023, Rock Springs Capital Management held 127 positions worth $4.2B, up 0.29% from $4.19B the previous quarter. Its ten largest holdings account for 34% of the portfolio.

Rock Springs Capital Management withdrew a net $165M in Q2 2023, closing 4 positions and reducing 16 holdings. Its most notable exit was Prometheus Biosciences, Inc. Common Stock, an estimated $111M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 97% a quarter earlier, followed by Consumer Staples and Industrials.

Against the trend, Rock Springs Capital Management opened a new position in Boston Scientific worth $14.5M.

  • Rock Springs Capital Management's largest Q2 2023 buy was Boston Scientific: 267,500 shares worth $14.5M.
  • Rock Springs Capital Management added most to Humana in Q2 2023, an estimated $21.9M increase.
  • Rock Springs Capital Management's biggest Q2 2023 reduction was Madrigal Pharmaceuticals, cutting an estimated $40.3M.
  • Rock Springs Capital Management fully exited Prometheus Biosciences, Inc. Common Stock in Q2 2023, selling an estimated $111M.
  • Rock Springs Capital Management's ten largest holdings make up 34% of its $4.2B portfolio in Q2 2023.
  • Rock Springs Capital Management opened 6 new positions and closed 4 in Q2 2023.
  • Rock Springs Capital Management's portfolio value rose 0.29% quarter-over-quarter to $4.2B.

Based on Rock Springs Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.